HIV self-testing and long-acting injectable options for commercial minibus drivers
Innovative Tools to Expand HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs)
['FUNDING_R01'] · GEORGE WASHINGTON UNIVERSITY · NIH-11170667
This project offers HIV self-tests and access to long-acting injectable prevention and treatment options to commercial minibus drivers in Nigeria to make testing and care easier around their busy schedules.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGE WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11170667 on ClinicalTrials.gov |
What this research studies
If you are a commercial minibus driver in Nigeria, this program will offer free HIV self-testing kits you can use privately and help link you to care if you test positive. The project also provides information and access to long-acting injectable ART for people living with HIV and long-acting injectable PrEP for people at risk, with support to keep injection appointments. The team will coordinate with local clinics and the National Institute of Medical Research to arrange follow-up, adherence support, and clinic visits that fit drivers' schedules. The approach adapts an earlier youth-focused HIV self-testing program to the needs of highly mobile drivers.
Who could benefit from this research
Good fit: Adult commercial minibus drivers working in the Nigerian study locations who are willing to try HIV self-testing or consider long-acting injectable PrEP or ART are the intended participants.
Not a fit: People who are not commercial drivers in the study areas, who cannot access participating clinics, or who prefer clinic-based testing and daily oral medications may not receive direct benefit from this program.
Why it matters
Potential benefit: If successful, this work could increase HIV testing and improve access and adherence to effective prevention and treatment for a hard-to-reach, high-risk group.
How similar studies have performed: Previous ITEST work showed promising results using HIV self-testing among youth in Nigeria, and long-acting injectable HIV drugs have been effective in clinical trials, but combining these tools for mobile drivers is a newer approach.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGE WASHINGTON UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CONSERVE, DONALDSON — GEORGE WASHINGTON UNIVERSITY
- Study coordinator: CONSERVE, DONALDSON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus